РОЛЬ ВЗАИМОДЕЙСТВИЙ МЕЖДУ НЕЙРОМЕДИАТОРАМИ ГОЛОВНОГО МОЗГА В ПАТОФИЗИОЛОГИИ И ЛЕЧЕНИИ АФФЕКТИВНЫХ РАССТРОЙСТВ
Ключевые слова:
серотонин (5-HT), норадреналин, допамин, глутамат, ГАМК, нейропептиды, гипоталамус, гиппокамп, потенциалзависимые кальциевые каналы
Аннотация
Целью настоящей обзорной статьи является обобщение известных на текущий момент данных о взаимодействиях между нейромедиаторами головного мозга и их роли в патофизиологии и лечении депрессии. Введение. Нейромедиаторы головного мозга представляют собой биологические молекулы, ответственные за передачу сигнала между нейронами. Нейромедиаторы головного мозга у млекопитающих относятся к разным типам биологических молекул, включающим аминокислоты (глутамат и ?-аминомасляную кислоту, или ГАМК), моноамины (серотонин (5-HT), норадреналин (НА), допамин (Д), а также гистамин (Г)), нейропептиды (?-эндорфин, нейрокинин, вазопрессин и окситоцин) и нуклеотиды (аденозин). Материалы и методы. Автор анализирует научные работы, изданные в период с 1953 по 2014 г. и посвященные нейромедиаторам и их функциям в регуляции настроения. Статья посвящена в первую очередь оценке данных о механизмах взаимодействия различных нейромедиаторов и их роли в развитии и лечении отдельных психических расстройств. Результаты. Согласно литературным источникам, нейромедиаторы, нередко относящиеся к разным типамбиологических молекул, взаимодействуют на поведенческом, функциональном, системном и молекулярном уровнях. Эти взаимодействия играют важную роль в патофизиологии заболеваний головного мозга, в частности, депрессии и стрессовых и тревожных расстройств. Заключение. Практически все существующие антидепрессанты воздействуют на моноаминовые системы головного мозга (5-HT, НЭ и Д). Невзирая на то, что антидепрессанты и стабилизаторы настроения последнего поколения обладают высокой степенью надежности и эффективности, их терапевтический потенциал пока ограничен. Большой интерес представляет разработка антидепрессантов, стабилизаторов настроения и нейролептиков, воздействующих на нейропередачу с участием аденозина. Однако такие препараты могут иметь серьезные побочные эффекты, например, негативно влиять на сердечную деятельность. Для разрешения существующих трудностей необходимо проведение дальнейших научных и клинических исследований.Литература
1. Airaksinen A.J., Jablonowski J.A., van der Mey M., Barbieret A.J. Radiosynthesis and Biodistribution of a Histamine H3 Receptor Antagonist 4-[3-(4-Piperidin-1-yl-But-1-Ynyl)-[11C]Benzyl]-Morpholine: Evaluation of a Potential PET Ligand. Nucl Med Biol (England), 2006, vol. 33, pp. 801–810.
2. Airaksinen M.S., Panula P. The Histaminergic System in the Guinea Pig Central Nervous System: An Immunocytochemical Mapping Study Using an Antiserum Against Histamine. J Comp Neurol (United States), 1988, vol. 273, pp. 163–186.
3. Airaksinen M.S., Flugge G., Fuchs E., Panula P. Histaminergic System in the Tree Shrew Brain. J Comp Neurol (United States), 1989, vol. 286, pp. 289–310.
4. Allmark M.G., Lu F.C., Carmichael E., Lavallee A. Some Pharmacological Observations on Isoniazid and Iproniazid. Ammerical Reviews in Tuberculosis, 1953, vol. 68, pp. 199–206.
5. Bakker R.A., Timmerman H., Leurs R. Histamine Receptors: Specific Ligands, Receptor Biochemistry, and Signal Transduction. Clin Allergy Immunol (United States). 2002, vol. 17, pp. 27–64.
6. Blier P., Montigny C. Serotoninergic But Not Noradrenergic Neurons in Rat Central Nervous System Adapt to Long-Term Treatment with Monoamine Oxidase Inhibitors. Neuroscience (England), 1985, vol. 16, pp. 949–955.
7. Blier P., Montigny C.D., Azzaro A.J. Modification of Serotonergic and Noradrenergic Neurotransmissions by Repeated Administration of Monoamine Oxidase Inhibitors: Electrophysiological Studies in the Rat Central Nervous System. J Pharmacol Exp Ther (United States), 1986, vol. 237, pp. 987–994.
8. Brown R.E., Stevens D.R., Haas H.L. The Physiology of Brain Histamine. Prog Neurobiol (England), 2001, vol. 63, pp. 637–672.
9. Connelly W.M., Shenton F.C., Lethbridge N. The Histamine H4 Receptor is Functionally Expressed on Neurons in the Mammalian CNS. Br J Pharmacol (England), 2009, vol. 157, pp. 55–63.
10. Corrodi H., Fuxe K. The Effect of Imipramine on Central Monoamine Neurons. J Pharm Pharmacol (England), 1968, vol. 20, pp. 230–231.
11. Cremers T.I., Rea K., Bosker F.J., Wikstromet H.V. Augmentation of SSRI Effects on Serotonin by 5-HT2C Antagonists: Mechanistic Studies. Neuropsychopharmacology (United States), 2007, vol. 32, pp. 1550–1557.
12. Cremers T.I., Giorgetti M., Bosker F.J., Hogg S., Arnt J. Inactivation of 5-HT(2C) Receptors Potentiates Consequences of Serotonin Reuptake Blockade. Neuropsychopharmacology (United States), 2004, vol. 29, pp. 1782–1789.
13. Delay J., Buisson J.F. Psychic Action of Isoniazid in the Treatment of Depressive States. Journal of Clinical and Experimental Psychopathololy, 1958, vol. 19. pp. 51–55.
14. Delgado P.L., Miller H.L., Salomon R.M. Tryptophan-Depletion Challenge in Depressed Patients Treated with Desipramine or Fluoxetine: Implications for the Role of Serotonin in the Mechanism of Antidepressant Action. Biol Psychiatry (United States), 1999, vol. 46, pp. 212–220.
15. Dremencov E., Mansari M.E., Blier P. Distinct Electrophysiological Effect of Paliperidone and Risperidone on the Firing Activity of Rat Serotonin and Norepinephrine Neurons. Psychopharmacology (Germany), 2007, vol. 194, pp. 63–72.
16. Dremencov E. Aiming at New Targets for the Treatment of Affective Disorders: An introduction. Curr Drug Targets (Netherlands), 2009, vol. 10, pp. 1050–1051.
17. Dremencov E., Mansari M.E., Blier P. Effects of Sustained Serotonin Reuptake Inhibition on the Firing of Dopamine Neurons in the Rat Ventral Tegmental Area. J Psychiatry Neurosci (Canada), 2009, vol. 34, pp. 223–229.
18. Dremencov E., Mansari M.E,, Blier P. Brain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications. Curr Drug Targets (Netherlands), 2009, vol. 10, pp. 1061–1068.
19. Dremencov E., Mansari M.E., Blier P. Noradrenergic Augmentation of Escitalopram Response by Risperidone: Electrophysiologic Studies in the Rat Brain. Biol Psychiatry, 2007, vol. 61, pp. 671–678.
20. Dremencov E., Gur E., Lerer B., Newman M.E. Effects of Chronic Antidepressants and Electroconvulsive Shock on Serotonergic Neurotransmission in the Rat Hippocampus. Prog Neuropsychopharmacol Biol Psychiatry (England), 2003, vol. 27, pp. 729–739.
21. Dremencov E., Gur E., Lerer B., Newman M.E. Effects of Chronic Antidepressants and Electroconvulsive Shock on Serotonergic Neurotransmission in the Rat Hypothalamus. Prog Neuropsychopharmacol Biol Psychiatry (England), 2002, vol. 26, pp. 1029–1034.
22. Dremencov E., Gispan-Herman I., Rosenstein M., Mendelman A., Overstreet D.H., Zohar J., Yadid G. The Serotonin-Dopamine Interaction is Critical for Fast-Onset Action of Antidepressant Treatment: In Vivo Studies in an Animal Model of Depression. Prog Neuropsychopharmacol Biol Psychiatry (England), 2004, vol. 28, pp. 141–147.
23. Mansari E.M., Guiard B.P., Chernoloz O., Ghanbari R., Katz N., Blier P. Relevance of Norepinephrine-Dopamine Interactions in the Treatment of Major Depressive Disorder. CNS Neurosci Ther (England), 2010, vol. 16, p. 17.
24. Guiard B.P., Mansari M.E., Merali Z., Blier P. Functional Interaction Between Monoaminergic Neurons. Biol Psychiatry, 2007, vol. 61, pp. 125–125.
25. Guiard B.P., Mansari E.M., Merali Z., Blier P. Functional Interactions Between Dopamine, Serotonin and Norepinephrine Neurons: An In-Vivo Electrophysiological Study in Rats with Monoaminergic Lesions. Int J Neuropsychopharmacol (England), 2008, vol. 11, pp. 625–639.
26. Haas H.L., Sergeeva O.A., Selbach O. Histamine in the Nervous System. Physiol Rev (United States), 2008, vol. 88, pp. 1183–1241.
27. Hew R.W., Hodgkinson C.R., Hill S.J. Characterization of Histamine H3-Receptors in Guinea-Pig Ileum with H3-Selective Ligands. Br J Pharmacol (England), 1990, vol. 101, pp. 621–624.
28. Iwase M., Homma I., Shioda S., Nakai Y. Histamine Immunoreactive Neurons in the Brain Stem of the Rabbit. Brain Res Bull (United States), 1993, vol. 32, pp. 267–272.
29. Kandel E.R., Schwartz J.H., Jessell T.M. Principles of Neural Science. New York: McGraw-Hill, Health Professions Division, 2000.
30. Kawahara Y., Kawahara H., Kaneko F., Tanaka M. Long-Term Administration of Citalopram Reduces Basal and Stress-Induced Extracellular Noradrenaline Levels in Rat Brain. Psychopharmacology (Germany), 2007, vol. 194, pp. 73–81.
31. Kennedy S.H. A Review of Antidepressant Treatments Today. Eur Neuropsychopharmacol (Netherlands), 2006, vol. 5, pp. 619–623.
32. Leurs R., Blandina P., Tedford C., Timmerman H. Therapeutic Potential of Histamine H3 Receptor Agonists and Antagonists. Trends Pharmacol Sci (England), 1998, vol. 19, pp. 177–183.
33. Lin J.S., Hou Y., Sakai K., Jouvet M. Histaminergic Descending Inputs to the Mesopontine Tegmentum and Their Role in the Control of Cortical Activation and Wakefulness in the Cat. J Neurosci (United States), 1996, vol. 16, pp. 1523–1537.
34. Martinez-Mir M.I., Pollard H., Moreau J., Arrang J.M., Ruat M., Traiffort E., Schwartz J.C., Palacios J.M. Three Histamine Receptors (H1, H2 and H3) Visualized in the Brain of Human and Non-Human Primates. Brain Res (Netherlands), 1990, vol. 526, pp. 322–327.
35. Moret C., Briley M. Effect of Antidepressant Drugs on Monoamine Synthesis in Brain in Vivo. Neuropharmacology (England), 1992, vol. 31, pp. 679–684.
36. Panula P., Pirvola U., Auvinen S., Airaksinen M.S. Histamine-Immunoreactive Nerve Fibers in the Rat Brain. Neuroscience (England), 1989, vol. 28, pp. 585–610.
37. Pollard H., Moreau J., Arrang J.M., Schwartz J.C. A Detailed Autoradiographic Mapping of Histamine H3 Receptors in Rat Brain Areas. Neuroscience (England), 1993, vol. 52, pp. 169–189.
38. Ravindran L., Kennedy S.H. Are Antidepressants as Effective as Claimed? Yes, But... Can J Psychiatry (Canada), 2007, vol. 52, pp. 98–99.
39. Robot M. Isoniazid and Its Psychological Effects. Annual Medical Psychology (Paris), 1954, vol. 112, pp. 161–183.
40. Salzer H.M., Lurie M.L. Depressive States Treated with Isonicotinyl Hydrazide (Isoniazid); A Follow-Up Study. Ohio Medicine, 1955, vol. 51, pp. 437–441.
41. Schlicker E., Malinowska B., Kathmann M., Gothert M. Modulation of Neurotransmitter Release Via Histamine H3 Heteroreceptors. Fundam Clin Pharmacol (France), 1994, vol. 8, pp. 128–137.
42. Schlicker E., Kathmann M., Detzner M., Exner H.J., Gothert M. H3 Receptor-Mediated Inhibition of Noradrenaline Release: An Investigation into the Involvement of Ca2+ and K+ Ions, G Protein and Adenylate Cyclase. Naunyn Schmiedebergs Arch Pharmacol (Germany), 1994, vol. 350, pp. 34–41.
43. Vanhala A., Yamatodani A., Panula P. Distribution of Histamine-, 5-Hydroxytryptamine-, and Tyrosine Hydroxylase-Immunoreactive Neurons and Nerve Fibers in Developing Rat Brain. J Comp Neurol (United States), 1994, vol. 347, pp. 101–114.
44. Vollinga R.C., Koning J.P., Jansen F.P., Leurs R., Menge W.M., Timmerman H. A New Potent and Selective Histamine H3 Receptor Agonist, 4-(1H-Imidazol-4-Ylmethyl) Piperidine. J Med Chem (United States), 1994, vol. 37, pp. 332–333.
2. Airaksinen M.S., Panula P. The Histaminergic System in the Guinea Pig Central Nervous System: An Immunocytochemical Mapping Study Using an Antiserum Against Histamine. J Comp Neurol (United States), 1988, vol. 273, pp. 163–186.
3. Airaksinen M.S., Flugge G., Fuchs E., Panula P. Histaminergic System in the Tree Shrew Brain. J Comp Neurol (United States), 1989, vol. 286, pp. 289–310.
4. Allmark M.G., Lu F.C., Carmichael E., Lavallee A. Some Pharmacological Observations on Isoniazid and Iproniazid. Ammerical Reviews in Tuberculosis, 1953, vol. 68, pp. 199–206.
5. Bakker R.A., Timmerman H., Leurs R. Histamine Receptors: Specific Ligands, Receptor Biochemistry, and Signal Transduction. Clin Allergy Immunol (United States). 2002, vol. 17, pp. 27–64.
6. Blier P., Montigny C. Serotoninergic But Not Noradrenergic Neurons in Rat Central Nervous System Adapt to Long-Term Treatment with Monoamine Oxidase Inhibitors. Neuroscience (England), 1985, vol. 16, pp. 949–955.
7. Blier P., Montigny C.D., Azzaro A.J. Modification of Serotonergic and Noradrenergic Neurotransmissions by Repeated Administration of Monoamine Oxidase Inhibitors: Electrophysiological Studies in the Rat Central Nervous System. J Pharmacol Exp Ther (United States), 1986, vol. 237, pp. 987–994.
8. Brown R.E., Stevens D.R., Haas H.L. The Physiology of Brain Histamine. Prog Neurobiol (England), 2001, vol. 63, pp. 637–672.
9. Connelly W.M., Shenton F.C., Lethbridge N. The Histamine H4 Receptor is Functionally Expressed on Neurons in the Mammalian CNS. Br J Pharmacol (England), 2009, vol. 157, pp. 55–63.
10. Corrodi H., Fuxe K. The Effect of Imipramine on Central Monoamine Neurons. J Pharm Pharmacol (England), 1968, vol. 20, pp. 230–231.
11. Cremers T.I., Rea K., Bosker F.J., Wikstromet H.V. Augmentation of SSRI Effects on Serotonin by 5-HT2C Antagonists: Mechanistic Studies. Neuropsychopharmacology (United States), 2007, vol. 32, pp. 1550–1557.
12. Cremers T.I., Giorgetti M., Bosker F.J., Hogg S., Arnt J. Inactivation of 5-HT(2C) Receptors Potentiates Consequences of Serotonin Reuptake Blockade. Neuropsychopharmacology (United States), 2004, vol. 29, pp. 1782–1789.
13. Delay J., Buisson J.F. Psychic Action of Isoniazid in the Treatment of Depressive States. Journal of Clinical and Experimental Psychopathololy, 1958, vol. 19. pp. 51–55.
14. Delgado P.L., Miller H.L., Salomon R.M. Tryptophan-Depletion Challenge in Depressed Patients Treated with Desipramine or Fluoxetine: Implications for the Role of Serotonin in the Mechanism of Antidepressant Action. Biol Psychiatry (United States), 1999, vol. 46, pp. 212–220.
15. Dremencov E., Mansari M.E., Blier P. Distinct Electrophysiological Effect of Paliperidone and Risperidone on the Firing Activity of Rat Serotonin and Norepinephrine Neurons. Psychopharmacology (Germany), 2007, vol. 194, pp. 63–72.
16. Dremencov E. Aiming at New Targets for the Treatment of Affective Disorders: An introduction. Curr Drug Targets (Netherlands), 2009, vol. 10, pp. 1050–1051.
17. Dremencov E., Mansari M.E., Blier P. Effects of Sustained Serotonin Reuptake Inhibition on the Firing of Dopamine Neurons in the Rat Ventral Tegmental Area. J Psychiatry Neurosci (Canada), 2009, vol. 34, pp. 223–229.
18. Dremencov E., Mansari M.E,, Blier P. Brain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications. Curr Drug Targets (Netherlands), 2009, vol. 10, pp. 1061–1068.
19. Dremencov E., Mansari M.E., Blier P. Noradrenergic Augmentation of Escitalopram Response by Risperidone: Electrophysiologic Studies in the Rat Brain. Biol Psychiatry, 2007, vol. 61, pp. 671–678.
20. Dremencov E., Gur E., Lerer B., Newman M.E. Effects of Chronic Antidepressants and Electroconvulsive Shock on Serotonergic Neurotransmission in the Rat Hippocampus. Prog Neuropsychopharmacol Biol Psychiatry (England), 2003, vol. 27, pp. 729–739.
21. Dremencov E., Gur E., Lerer B., Newman M.E. Effects of Chronic Antidepressants and Electroconvulsive Shock on Serotonergic Neurotransmission in the Rat Hypothalamus. Prog Neuropsychopharmacol Biol Psychiatry (England), 2002, vol. 26, pp. 1029–1034.
22. Dremencov E., Gispan-Herman I., Rosenstein M., Mendelman A., Overstreet D.H., Zohar J., Yadid G. The Serotonin-Dopamine Interaction is Critical for Fast-Onset Action of Antidepressant Treatment: In Vivo Studies in an Animal Model of Depression. Prog Neuropsychopharmacol Biol Psychiatry (England), 2004, vol. 28, pp. 141–147.
23. Mansari E.M., Guiard B.P., Chernoloz O., Ghanbari R., Katz N., Blier P. Relevance of Norepinephrine-Dopamine Interactions in the Treatment of Major Depressive Disorder. CNS Neurosci Ther (England), 2010, vol. 16, p. 17.
24. Guiard B.P., Mansari M.E., Merali Z., Blier P. Functional Interaction Between Monoaminergic Neurons. Biol Psychiatry, 2007, vol. 61, pp. 125–125.
25. Guiard B.P., Mansari E.M., Merali Z., Blier P. Functional Interactions Between Dopamine, Serotonin and Norepinephrine Neurons: An In-Vivo Electrophysiological Study in Rats with Monoaminergic Lesions. Int J Neuropsychopharmacol (England), 2008, vol. 11, pp. 625–639.
26. Haas H.L., Sergeeva O.A., Selbach O. Histamine in the Nervous System. Physiol Rev (United States), 2008, vol. 88, pp. 1183–1241.
27. Hew R.W., Hodgkinson C.R., Hill S.J. Characterization of Histamine H3-Receptors in Guinea-Pig Ileum with H3-Selective Ligands. Br J Pharmacol (England), 1990, vol. 101, pp. 621–624.
28. Iwase M., Homma I., Shioda S., Nakai Y. Histamine Immunoreactive Neurons in the Brain Stem of the Rabbit. Brain Res Bull (United States), 1993, vol. 32, pp. 267–272.
29. Kandel E.R., Schwartz J.H., Jessell T.M. Principles of Neural Science. New York: McGraw-Hill, Health Professions Division, 2000.
30. Kawahara Y., Kawahara H., Kaneko F., Tanaka M. Long-Term Administration of Citalopram Reduces Basal and Stress-Induced Extracellular Noradrenaline Levels in Rat Brain. Psychopharmacology (Germany), 2007, vol. 194, pp. 73–81.
31. Kennedy S.H. A Review of Antidepressant Treatments Today. Eur Neuropsychopharmacol (Netherlands), 2006, vol. 5, pp. 619–623.
32. Leurs R., Blandina P., Tedford C., Timmerman H. Therapeutic Potential of Histamine H3 Receptor Agonists and Antagonists. Trends Pharmacol Sci (England), 1998, vol. 19, pp. 177–183.
33. Lin J.S., Hou Y., Sakai K., Jouvet M. Histaminergic Descending Inputs to the Mesopontine Tegmentum and Their Role in the Control of Cortical Activation and Wakefulness in the Cat. J Neurosci (United States), 1996, vol. 16, pp. 1523–1537.
34. Martinez-Mir M.I., Pollard H., Moreau J., Arrang J.M., Ruat M., Traiffort E., Schwartz J.C., Palacios J.M. Three Histamine Receptors (H1, H2 and H3) Visualized in the Brain of Human and Non-Human Primates. Brain Res (Netherlands), 1990, vol. 526, pp. 322–327.
35. Moret C., Briley M. Effect of Antidepressant Drugs on Monoamine Synthesis in Brain in Vivo. Neuropharmacology (England), 1992, vol. 31, pp. 679–684.
36. Panula P., Pirvola U., Auvinen S., Airaksinen M.S. Histamine-Immunoreactive Nerve Fibers in the Rat Brain. Neuroscience (England), 1989, vol. 28, pp. 585–610.
37. Pollard H., Moreau J., Arrang J.M., Schwartz J.C. A Detailed Autoradiographic Mapping of Histamine H3 Receptors in Rat Brain Areas. Neuroscience (England), 1993, vol. 52, pp. 169–189.
38. Ravindran L., Kennedy S.H. Are Antidepressants as Effective as Claimed? Yes, But... Can J Psychiatry (Canada), 2007, vol. 52, pp. 98–99.
39. Robot M. Isoniazid and Its Psychological Effects. Annual Medical Psychology (Paris), 1954, vol. 112, pp. 161–183.
40. Salzer H.M., Lurie M.L. Depressive States Treated with Isonicotinyl Hydrazide (Isoniazid); A Follow-Up Study. Ohio Medicine, 1955, vol. 51, pp. 437–441.
41. Schlicker E., Malinowska B., Kathmann M., Gothert M. Modulation of Neurotransmitter Release Via Histamine H3 Heteroreceptors. Fundam Clin Pharmacol (France), 1994, vol. 8, pp. 128–137.
42. Schlicker E., Kathmann M., Detzner M., Exner H.J., Gothert M. H3 Receptor-Mediated Inhibition of Noradrenaline Release: An Investigation into the Involvement of Ca2+ and K+ Ions, G Protein and Adenylate Cyclase. Naunyn Schmiedebergs Arch Pharmacol (Germany), 1994, vol. 350, pp. 34–41.
43. Vanhala A., Yamatodani A., Panula P. Distribution of Histamine-, 5-Hydroxytryptamine-, and Tyrosine Hydroxylase-Immunoreactive Neurons and Nerve Fibers in Developing Rat Brain. J Comp Neurol (United States), 1994, vol. 347, pp. 101–114.
44. Vollinga R.C., Koning J.P., Jansen F.P., Leurs R., Menge W.M., Timmerman H. A New Potent and Selective Histamine H3 Receptor Agonist, 4-(1H-Imidazol-4-Ylmethyl) Piperidine. J Med Chem (United States), 1994, vol. 37, pp. 332–333.
References
Опубликован
2016-06-01
Как цитировать
Дременков, Э. (2016). РОЛЬ ВЗАИМОДЕЙСТВИЙ МЕЖДУ НЕЙРОМЕДИАТОРАМИ ГОЛОВНОГО МОЗГА В ПАТОФИЗИОЛОГИИ И ЛЕЧЕНИИ АФФЕКТИВНЫХ РАССТРОЙСТВ. Человек. Спорт. Медицина, 16(2), 18-29. https://doi.org/10.14529/hsm160202
Выпуск
Раздел
Клиническая и экспериментальная медицина
Copyright (c) 2019 Человек. Спорт. Медицина
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
